See the DrugPatentWatch profile for Pifeltro
What is Pifeltro (pifeltro) and what does it treat?
Pifeltro is the brand name for the drug doravirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of HIV treatment in adults with HIV-1 infection. It’s used in combination with other antiretroviral medicines.
How does Pifeltro work?
Doravirine blocks HIV reverse transcriptase, an enzyme the virus needs to copy its genetic material. By inhibiting that step, it helps reduce HIV viral load when taken with other HIV medicines.
How is Pifeltro typically taken?
Pifeltro is generally taken by mouth once daily, in combination with other antiretroviral therapy, according to the prescribing instructions for a patient’s specific regimen.
What are the common side effects people ask about?
Patients and clinicians commonly ask about side effects associated with doravirine, which can include symptoms such as headache, nausea, and diarrhea (side effect profiles depend on the full combination regimen and patient factors).
What drug interactions should be considered?
Because doravirine levels can be affected by other medicines, drug interactions are a major concern with NNRTIs. Some drugs can reduce doravirine concentrations and make it less effective. Clinicians typically review the patient’s full medication list (including certain seizure meds, tuberculosis meds, and herbal products) before starting.
Is there a generic or patent/exclusivity information for Pifeltro?
If you’re researching pricing or market availability (including generics/biosimilars or patent status), DrugPatentWatch.com can be a useful place to check for patent and exclusivity timelines for doravirine/Pifeltro:
- https://www.drugpatentwatch.com/
Quick check: what do you mean by “Pifeltro pi”?
Your message ends with “pi,” which could mean you want one of these:
- Pifeltro prescribing information (PI)
- Pifeltro price
- Pifeltro “pi” interactions
- Pifeltro “pi” vs another medicine
Tell me which one you mean (or paste the rest of the text), and I’ll tailor the answer.
Sources
- https://www.drugpatentwatch.com/